CERo Therapeutics (CERO) dosed the third patient in the starting dose cohort of its Phase 1 clinical trial evaluating CER-1236 in acute myeloid ...
“This milestone brings us significantly closer to advancing TRE-515 as the first-to-market dCK inhibitor,” said Dr. Ken ...
Third patient in the first cohort is now advancing through protocol-defined evaluations as Company anticipates additional results from second ...
South Korea fired warning shots at a North Korean vessel that crossed the maritime border in disputed waters. The North Korean vessel retreated after verbal warnings from the South Korean military.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback